Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Van Veen

Showing results (1-10 of 98) with videos related to

Pageof 10
Sort By:
Acta Haematologica|April 25, 2008
Altitude and coagulation activation: does going high provoke thrombosis?J J van Veen, M Makris
Blood Transfusion = Trasfusione Del Sangue|January 22, 2011
Three or four factor prothrombin complex concentrate for emergency anticoagulation reversal?Mike Makris, Joost J Van Veen
Journal of Thrombosis and Haemostasis : JTH|April 22, 2005
Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity--a rebuttalM Makris, J J Van Veen
Anaesthesia|December 3, 2014
Management of peri-operative anti-thrombotic therapyJ J van Veen, M Makris
Journal of Thrombosis and Haemostasis : JTH|October 25, 2011
Reduced cardiovascular mortality in hemophilia despite normal atherosclerotic loadMike Makris, J J Van Veen
Nederlands Tijdschrift Voor Geneeskunde|June 16, 2011
[A man with thoracic pain]Martin J van Veen, Joost M Klaase
British Journal of Haematology|August 30, 2002
Kilt syndrome?J Van Veen, K K Hampton, M Makris
International Journal of Laboratory Hematology|May 1, 2018
Argatroban is stable in citrated whole blood for 24 hoursS Guy, S Kitchen, J J Van Veen
International Journal of Clinical Practice|August 21, 2010
Recombinant factor VIIa for unlicensed indications--a definite No or a cautious Maybe in selected patients?Y Sorour, J J Van Veen, M Makris
British Journal of Haematology|October 28, 2016
Further evidence of the limitations of Activated Partial Thromboplastin Time to monitor ArgatrobanSusan Guy, Steve Kitchen, Joost J Van Veen
Pageof 10

Showing results (1-10 of 98) with videos related to

Sort By:
Pageof 10
Acta Haematologica|April 25, 2008
Altitude and coagulation activation: does going high provoke thrombosis?J J van Veen, M Makris
Blood Transfusion = Trasfusione Del Sangue|January 22, 2011
Three or four factor prothrombin complex concentrate for emergency anticoagulation reversal?Mike Makris, Joost J Van Veen
Journal of Thrombosis and Haemostasis : JTH|April 22, 2005
Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity--a rebuttalM Makris, J J Van Veen
Anaesthesia|December 3, 2014
Management of peri-operative anti-thrombotic therapyJ J van Veen, M Makris
Journal of Thrombosis and Haemostasis : JTH|October 25, 2011
Reduced cardiovascular mortality in hemophilia despite normal atherosclerotic loadMike Makris, J J Van Veen
Nederlands Tijdschrift Voor Geneeskunde|June 16, 2011
[A man with thoracic pain]Martin J van Veen, Joost M Klaase
British Journal of Haematology|August 30, 2002
Kilt syndrome?J Van Veen, K K Hampton, M Makris
International Journal of Laboratory Hematology|May 1, 2018
Argatroban is stable in citrated whole blood for 24 hoursS Guy, S Kitchen, J J Van Veen
International Journal of Clinical Practice|August 21, 2010
Recombinant factor VIIa for unlicensed indications--a definite No or a cautious Maybe in selected patients?Y Sorour, J J Van Veen, M Makris
British Journal of Haematology|October 28, 2016
Further evidence of the limitations of Activated Partial Thromboplastin Time to monitor ArgatrobanSusan Guy, Steve Kitchen, Joost J Van Veen
Pageof 10